Drug intelligence / Profile preview

HLK-0010

Development stage: Preclinical
Lead developer: HLK Pharmacin
Modality: Small Molecules

Overview

HLK-0010 is an investigational drug candidate being developed by Shenzhen Pharmacin for the treatment of melanoma. It is currently in the early formulation and preclinical stages of development. Shenzhen Pharmacin focuses on the 505(b)(2) regulatory pathway, utilizing proprietary technology platforms such as SpraySol™ to develop improved formulations of existing active pharmaceutical ingredients. These technologies are typically aimed at enhancing the solubility, bioavailability, or delivery profile of small molecule drugs. Specific details regarding the active ingredient and molecular target of HLK-0010 have not yet been publicly disclosed.

Beyond the preview

Go deeper on HLK-0010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLK-0010.

Explore the full profile